PhewyPompipi
2021-08-12
Fantastic positive news! Keeping fingers crossed!
BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
7
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":894097920,"tweetId":"894097920","gmtCreate":1628776934260,"gmtModify":1631891607569,"author":{"id":4087475573507020,"idStr":"4087475573507020","authorId":4087475573507020,"authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Fantastic positive news! Keeping fingers crossed!</p></body></html>","htmlText":"<html><head></head><body><p>Fantastic positive news! Keeping fingers crossed!</p></body></html>","text":"Fantastic positive news! Keeping fingers crossed!","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/894097920","repostId":2158325931,"repostType":4,"repost":{"id":"2158325931","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628776169,"share":"https://www.laohu8.com/m/news/2158325931?lang=&edition=full","pubTime":"2021-08-12 21:49","market":"us","language":"en","title":"BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster","url":"https://stock-news.laohu8.com/highlight/detail?id=2158325931","media":"Tiger Newspress","summary":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previo","content":"<p>BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-12 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158325931","content_text":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.\n\nBioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.\nThe WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.\nThere is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.\nBioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.\nThe conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.\nPfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.","news_type":1},"isVote":1,"tweetType":1,"viewCount":192,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":44,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/894097920"}
精彩评论